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Background: The role of exosomes in the pathogenesis and metastatic spread of cancer remains to be fully
elucidated. Recent studies support the hypothesis that the release of exosomes from cells modifies local
extracellular conditions to promote cell growth and neovascularisation. In addition, exosomes may modify the
phenotype of parent and/or target cell. For example, sequestration of signaling mediators into exosomes may
reduce their intracellular bioavailability to the parent cell thereby altering cell phenotype and metastatic potential.
The fusion of released exosomes with target cell and delivery may also modify cell function and activity. In this
study, to further elucidate the role of exosomes in ovarian cancer, the release of exosomes from two ovarian cancer
cell lines of different invasive capacity and their miRNA content of exosomes were compared. The hypothesis to be
tested was that ovarian cancer cell invasiveness is associated with altered release of exosomes and discordant
exosomal sequestration of miRNA.
Methods: High (SKOV-3) and low (OVCAR-3) invasive ovarian cancer cell lines were used to characterize their
exosome release. SKOV-3 and OVCAR-3 cells were cultured (DMEM, 20% exosome-free FBS) under an atmosphere of
8% O2 for 24 hours. Cell-conditioned media were collected and exosomes were isolated by differential and buoyant
density centrifugation and characterised by Western blot (CD63 and CD9). Exosomal microRNA (let-7a-f and
miR-200a-c) content was established by real-time PCR.
Results: Exosomes were identified with by the presence of typical cup-shaped spherical vesicle and the expression
of exosome markers: CD63, CD9. SKOV-3 cells released 2.7-fold more exosomes (1.22 ± 0.11 μg/106 cells) compared
to OVCAR-3 (0.44 ± 0.05 μg/106 cells). The let-7 family miRNA transcripts were identified in both ovarian cancer cell
lines and their exosomes. The let-7 family transcripts were more abundant in OVCAR-3 cell than SKOV-3 cells. In
contrast, let-7 family transcripts were more abundant in exosomes from SKOV-3 than OVCAR-3. miR-200 family
transcripts were only identified in OVCAR-3 cells and their exosomes.
Conclusions: The data obtained in this study are consistent with the hypothesis that the releases of exosomes
varies significantly between ovarian cancer cell lines and correlates with their invasive potential.
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Ovarian cancer continues to be the leading causes of death
among women with gynaecological cancer with 225,500
new cases reported each year, causing over 140,200 deaths
annually worldwide [1]. Although ovarian cancer accounts
for 3% of all cancer incidents, 6% of cancer-related death
is caused by ovarian cancer, making it the fifth leading
cause of cancer mortality in women [2]. While progress
has been achieved in our understanding of aetiology and
risk factor for ovarian cancer research, there has been little
improvement in survival rates [2]. Ovarian cancer con-
tinues to be a challenging public health issue.
The keystone to improving health outcomes remains
the timely and accurate diagnosis of the predisposition
to, or early detection of disease. Early detection of
disease risk and onset is the first step in implementing
efficacious treatment and improving patient outcome. In
the context of ovarian cancer, despite recent progress in
chemotherapeutic treatments, the diagnosis of late stage
disease is associated with a five-year survival rate of ~30%.
In contrast, when ovarian cancer is identified at an early
stage, five year survival increases to ~90% [3]. Thus, the
development of more accurate and earlier detection tests
for this disease is undoubtedly the number one priority
for achieving long- term reduction of mortality from ovar-
ian cancer. To date, such tests have not been developed
and the use of traditional biomarker approaches and
screening methods have failed to deliver significant clinical
outcomes. New approaches to the development of in vitro
diagnostics that deliver greater diagnostic sensitivity are
required.
Recent studies highlight the putative utility of tissue-
specific nanovesicles (e.g. exosomes) in the diagnosis of dis-
ease onset and treatment monitoring [4,5]. To date, there
are only limited data defining changes in the release, role
and diagnostic utility of ovarian cancer-derived exosomes.
Exosomes are small (40–90 nm) membrane vesicles of
endocytic origin. The biogenesis of exosomes is initiated
by the inward budding of multivescular bodies (MVB),
encapsulating cellular proteins and RNA molecules to
form internal vesicles. Exosomes are released from sev-
eral cell types including cancer cells into the peripheral
circulation and are detected in biofluids such as plasma,
saliva, urine and breast milk [6,7].
Tumour-derived exosomes may affect cancer progres-
sion in several ways. Tumour-derived exosomes have the
ability to propagate oncogenic activity among tumour cells.
Exosomes are not only mediators of cell-to-cell com-
munication but also represent an attractive source of
cancer biomarkers due to the following features: exosomes
are (i) actively released from living tumour cells; (ii) con-
vey information about tumour state; (iii) easily obtained
from biofluids; easily isolated from high-abundance pro-
teins that confound biomarker discovery; and (iv) are highstability. Most importantly, exosomes are being secreted
from living tumour cells and are distinct from apoptotic
cell-derived microvesicles [8]. As exosomes contain cellu-
lar protein and RNA molecules in cell type-specific man-
ner, they may provide extensive information about the
signature of the tumour [9]. Exosomes have been reported
to express a diverse range of cell surface receptors, pro-
teins (including, heat shock proteins, cytoskeletal proteins,
adhesion molecules, membrane transport and fusion pro-
teins) and miRNA with the potential to affect the acute
and long-term function of the cells with which they inter-
act. miRNA is a class of small (approximately 22 nt long),
non-coding RNAs that negatively regulate gene expression
by binding to the 3′ untranslated region of target mRNAs
[10,11]. Once the miRNA is bound, the target messenger
RNA (mRNA) is either cleaved for degradation or its
translation is inhibited [12]. miRNAs are evolutionary
conserved across species, reinforcing the vast influence of
miRNAs on essential biological processes such as differen-
tiation, proliferation, apoptosis [10,12,13]. Deregulation of
these miRNAs will not only impact normal physiological
processes but also implicated in diseases including cancer.
Previous studies have established the significant difference
in ovarian cancer miRNA profiles, reinforcing miRNA as
a promising cancer biomarker, most studies, however,
have examined the miRNA profile of tumour tissues. The
collection of tissue samples is an invasive procedure and
unsuitable for a diagnostic and screening tests. The utility
of cell-free miRNA in biofluids has been investigated as a
source of cancer biomarkers. Although this approach
overcomes the issue of sample collection, the question
remains on how miRNAs are released and avoid degrad-
ation. Currently, limited data are available on the mechan-
ism of free miRNA release. The origin of these miRNAs
remains unclear and they may be released from apoptotic
cells. If this is the case, free miRNAs may not be a useful
indicator of tumours state and/or progression.
The let-7 family of miRNAs comprises 10 mature iso-
forms and is important in development and cell fate con-
trol. They are initially expressed as primary (pri)miRNA in
the form of a hairpin loop and the base is removed by
RNaseII enzyme, Drosha, to form pre-miRNA. PremiRNA
is then exported from nucleus to cytoplasm where another
RNaseII enzyme, Dicer, cleaves the loop region to produce
the mature miRNA. The mature miRNA is incorporated
into the RNA induced silencing complex as a guide for
target mRNA [14]. Let-7 expression is deregulated in ag-
gressive high-grade ovarian cancer [15]. In addition, miR-
200 family (i.e. miR-200a, miR-200b and miR-200c) has
been associated with ovarian cancer progression [16]. We
hypotheses that (i) the release of exosomes from ovarian
cancer cell lines is responsive to changes with invasiveness
capacity; and (ii) exosomal miRNA content is cell type
specific.
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invasiveness is associated with altered release of exosomes
and discordant exosomal sequestration of miRNA. Two
ovarian cancer cell lines of epithelial cell origin but with
different invasive potentials (SKOV-3 and OVCAR-3)
were used to test the hypotheses.
Methods
Ovarian cancer cell lines
This study was approved by the Human Research Ethics
Committees of the Royal Brisbane and Women’s Hospital,
and the University of Queensland (HREC/09/QRBW/14).
All experimental procedures were conducted within an
ISO17025 accredited (National Association of Testing
Authorities, Australia) research facility. All data were
recorded within a 21 CRF part 11 compliant electronic
laboratory notebook (Irisnote, Redwood City, CA, USA).
The human ovarian cancer cell lines OVCAR-3 and
SKOV-3 (with more invasive capacity than OVCAR-3)
[17] were obtained from the American Type Cell Collection
and were cultured in RPMI media (Life technologies,
USA) supplemented with 10% fetal bovine serum (FBS;
PAA, Australia). Cell cultures were incubated at 37°C in
8% O2 and 5% CO2 atmosphere. Cell confluence and
morphology were routinely checked, cells washed with
phosphate buffered saline (PBS; Life technologies, USA)
and fresh growth media was added every two to three days.
Cells were subcultured with dissociation media, TrypLE™
Express (Life technologies, USA) and cellular viability
was determined by Trypan Blue exclusion and Countess®
Automated cell counter (Life Technologies, USA).
Invasion assay of OVCAR-3 and SKOV-3
Cell invasion rates were established using our previously
published method [18,19]. Using a real-time cell imaging
system (IncuCyte™ (Essen BioScience, Michigan, USA).
In brief, 96-well plates were coated with a thin layer of
collagen by transferring 300 μg/ml of collagen type I
(Life Technologies™, Carlsbad, CA) and incubating at 37°C
for 30 min. OVCAR-3 and SKOV-3 (2 × 104 cells per well)
were grown to confluence in complete growth media. Cell-
free zones were created by generating a wound with a
96-Well WoundMaker™ (Essen BioScience, Michigan, USA).
The cells were overlaid with 3 mg/ml collagen type I (Life
Technologies™, Carlsbad, CA) and incubated at 37°C for
30 min to create a 3D matrix. Complete growth media was
added on top of the layer of collagen. Cells were imaged
automatically every 3 h over a time period of 48 h. The
images were processed by the IncuCyte™ software package
(Essen BioScience, Michigan, USA) to measure cell inva-
sion by obtaining the Relative Wound Density (RWD, as
defined by custom algorithms within the IncuCyte™ soft-
ware package). These users informed algorithms identify
the wound region and provide visual representations ofthe segmentation parameters. Image collection was created
using three to five representative phase contrast images.
Exosome isolation from cell-cultured media
Prior to exosome isolation, cell cultures grown above 70%
confluence were washed with PBS and exosome-free media
was added. Exosome-free media composed of RPMI media
supplemented with 20% exosome-depleted FBS and 5%
antibiotic-antimycotic (Life technologies, USA). Exosomes
were removed from FBS by ultracentrifuging at 100,000 × g
for 21 h at 4°C and filtering the resulting supernatant with
0.22 μm filter (Millipore, Massachusetts, USA). The cells
were incubated in exosome-free media for 24 h at 37°C in
8% O2 and 5% CO2 atmosphere. The following day, exo-
somes were isolated from cell-cultured media by differ-
ential ultracentrifugation as previously described [18,19]
Cell-conditioned cultured media was centrifuged suc-
cessively at increasing speed: (i) 300 × g for 5 min 4°C,
(ii) 1200 × g for 10 min 4°C, (iii) 10,000 × g for 30 min 4°C,
(iv) 100,000 × g for 75 min 4°C. After each step, the pellet
was discarded and the supernatant was quantified and
used for the following step. The resulting pellet after
the fourth step was resuspended in PBS and washed at
100,000 × g for 70 min 4°C to remove any contaminat-
ing proteins. The pellet was resuspended in PBS, layered
on a cushion of 30% (w/v) sucrose and centrifuged at
110,000 g for 75 min for purification. The fraction con-
taining OVCAR-3 and SKOV-3 exosomes (~3.5 ml, 1.127
density using OPTi digital refractometer (Bellingham+
Stanley Inc., Lawrenceville, GA, USA) was recovered with
an 18-G needle and diluted in PBS, and then centrifuged
at 110 000 × g of 70 min.
Cell count and viability
Cells were washed with PBS and dissociated with TrypLE™
Express (Life technologies, USA). The number and viabil-
ity of cells were determined to further calculate the
amount of exosome release from one million cells. Col-
lected cells were incubated with Trypan Blue, cell number
and viability were assessed using a Countess® automated
cell counter (Invitrogen™, USA).
Exosomal and cellular protein quantification
Amount of exosomes secreted were estimated by meas-
uring the total protein present within exosomes by the
BIO-RAD DC™ Protein Assay (USA). Exosome samples
were prepared by adding RIPA buffer directly to exo-
somes suspended in PBS and sonicated at 40°C for 15 s
three times to lyse exosome membrane and solubilise
the proteins. Bovine serum albumin (BSA) diluted in
RIPA and PBS mixture (1:1) were prepared as protein
standards at 0, 200, 400, 600, 800, 1000, 1500 μg/mL.
Standards and samples (prepared exosomes and cell
lysate) were transferred to 96-well plates and procedures
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alkaline copper tartrate solution (BIO-RAD, USA) and
dilute Folin Reagent (BIO-RAD, USA) were added to
the samples and incubated for 15 min. The absorbance
was read at 750 nm with Paradigm Detection Platform
(Beckman Coulter, USA).
Western Blot
Exosome markers were identified by Western blot accord-
ing to our previously published methods [18]. In brief,
10 μg of exosomal proteins were separated on NuPAGE
4-12% Bis-Tris Gel (Life Technologies, USA). Separated
proteins were transferred to Immobilon-®FL polyvinylidene
difluoride membrane (Millipore, Billerica, MA, USA)
in transfer buffer (5% NuPAGE® Transfer buffer, 20%
methanol) for 1 hour at 100 V. The membrane was washed
in wash buffer (PBS TWEEN 0.1%) three times for 10 min
and blocked with 5% skim milk in PBS TWEEN (0.1%) for
an hour at room temperature under agitation. The blocked
membrane was further probed for previously identified
exosome-specific markers: primary mouse monoclonal
anti-CD63 (1:1000, Abcam®) or anti-CD9 (1:1000, Abcam®).
This was done by incubating the membrane in primary
antibody diluted in 5% skim milk in PBS TWEEN (0.1%) at
4°C overnight on the laboratory rocker. After an overnight
incubation, the membrane was washed with wash buffer
and exposed to secondary antibody, donkey anti mouse
IgG-HRP (1:1000, Santa Cruz Biotechnology) diluted in
5% skim milk in PBS TWEEN (0.1%) for 1 h at room
temperature under agitation. The membrane was washed
3 times for 10 min in wash buffer. Bound antibodies were
detected by enhanced chemiluminescence (peroxide buf-
fer and enhancer buffer, Thermo Scientific) and visualised
with the SRX-101A Tabletop Processor (Konica Minolta,
Ramsey, NJ, USA).
Transmission electron microscopy
The exosome fraction isolated by differential and buoy-
ant density gradient centrifugation was assessed by
transmission electron microscopy as described [18,19].
Exosome pellets were fixed in 3% (w/v) glutaraldehyde
and 2% paraformaldehyde in cacodylate buffer, pH 7.3
and the sample was then applied to a continuous carbon
grid and negatively stained with 2% uranyl acetate. The
samples were examined in an FEI Tecnai 12 transmission
electron microscope (FEI™, Hillsboro, Oregon, USA).
Nanoparticle tracking analysis
The size distribution of exosome preparations was analysed
using a NanoSight LM10 system (NanoSight, Amesbury,
UK) according to the manufacturer’s instructions. Exosome
samples isolated from OVCAR-3 and SKOV-3 cells were
diluted in PBS 1X 1:3 and 1:6, respectively before theanalysis. The instrument measured the rate of Brownian
motion of nanoparticles [20].
Quantification of ovarian cancer cell-derived exosome
Exosome concentration was determined using the total
exosomal CD63 protein measured by ELISA (ExoELISA™,
System Biosciences, Mountain View, CA) according to the
manufacturer’s instructions. Quantitative results (number
of exosome particles) were obtained using a exosome pro-
tein standard curve calibrated by NanoSight instrument
provide by ExoELISA™ kit.
miRNA isolation
Ambion mirVana PARIS Kit (Invitrogen, USA) was used
to extract cellular and exosomal total RNA from OVCAR-3
and SKOV-3 by following the manufacturer’s procedure.
Cell samples were prepared by trypsinising the cells and
centrifuging at 300 × g for 5 min to remove the super-
natant. Samples are first lysed by adding cell disruption
buffer and vortexed or pipetted vigorously. Denaturing
solution was added to samples and incubated on ice for
5 min. The first two steps stabilize RNA and inactivate
RNases. The lysate is then subjected to Acid-Phenol:
Chloroform extraction by adding Acid-Phenol:Chloro-
form, vortexed and centrifuged at 10,000 × g for 5 min.
Recovery of the aqueous phase obtains semi-pure RNA
samples, removing most of the other cellular compo-
nents. 100% ethanol was mixed and passed through a
filter cartilage. The filter was washed three times and
the RNA was eluted with nuclease-free water.
Real-time PCR
Reverse transcription was performed using the miScript
Reverse Transcription Kit (QIAGEN, Valencia, CA, USA)
in a total volume of 20 μl. cDNA was synthesised from the
maximum volume of OVCAR-3 and SKOV-3 exosomal
RNA (12 μl) using the BIO-RAD T100™ Thermal Cycler
(USA) running for 60 min at 37°C, 5 min for 95°C and
60 min for 37°C. As the control, RNase-free water was
added as the RNA template. Real-time PCR was performed
with miScript SYBR Green Kit (QIAGEN, Valencia, CA,
USA). Forward primers (miScript primer assays, QIAGEN,
Valencia, CA, USA) designed to detect the following ma-
ture miRNAs were used: let-7 family (Hs_let-7a_2,
Hs_let-7b_1, Hs_let-7c-1, Hs_let-7d_2, Hs_let-7e_3, and
Hs_let-7f_1) and miR-200 family (Hs_miR-200a_1, Hs_
miR-200b_3, Hs_miR-200c_1). The universal primer in-
cluded in the kit was used as the reverse primer. The
reactions were performed in triplicate using the BIO-RAD
iQ™5 Multicolor Real-Time PCR Detection System (USA)
with the following conditions: 94°C for 3 min, 35 amplifica-
tion cycles of 94°C for 45 s, 55°C for 30 s and 72°C for 30 s,
72°C for 10 min, 12°C for ∞ min. Let-7 miRNA and miR-
200 expression was normalized (ΔCT) to the recommended
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ΔCT =CTLET-7 or miR-200 - CTRNU6B. The data are presented
as 2-ΔCT. miRNA transcript expression from the same
amount of RNA (Ambion mirVana PARIS Kit) was mea-
sured. RNU6-2 expression was consistent in all the sam-
ples both within and across experimental conditions. No
statistically significant differences (p > 0.05) in the expres-
sion of RNU6-2 between exosomes and/or cells samples
measured by Standard Deviation of CT were identified.
Statistical analysis
All studies conducted were treatment – control compar-
isons, with at least 3 independent experiments (n value)
performed. Data are presented as mean ± SEM (n value).
Comparisons between two or more groups were performedFigure 1 Ovarian cancer cell invasion. OVCAR-3 and SKOV-3 cells were g
well WoundMaker and then overlaid to form a 3D matrix-gel. Invasion assa
Cells were imaged with IncuCyte™ (Essen BioSciences, USA) every three hours
and SKOV-3 (A5-A8) cell invasion. A1 and A5: phase contrast micrograph imag
showing the calculation of initial wound width; A3 and A7: cells images show
24 hours of the experiment. The grey region denotes the area of the initial w
SKOV-3 invasion. (C) Area under curves analysis from B. Data represented as mby means of unpaired Student’s t-test and analysis of vari-
ance (ANOVA), respectively. Statistical significance was
defined at least p < 0.05 determined using the GraphPad
Prism software, Inc.
Results
Characterisation of human epithelial ovarian cancer
cell lines
Initially, studies were conducted to confirm the invasive-
ness of the two ovarian cancer cell lines (OVCAR-3 and
SKOV-3 cells) used in these studies. Figure 1A presents
photomicrographs of wound closure over 24 h incuba-
tion for both cell lines and the percent change in relative
wound density over time (Figure 1B). Figure 1C presents
cell invasion expressed as area under the curve (AUC) ofrown to confluence in complete media. A wound was made using 96
y was preformed with OVCAR-3 and SKOV-3 cells in complete media.
for 24 h. (see Methods). (A) Representative images of OVCAR-3 (A1-A4)
e immediately after wounding; A2 and A6: graphical representation
24 hours later; A4 and A8: graphical representation of cell invasion at
ound covered by advancing cells. (B) The time course of OVCAR-3 and
ean ± SEM (n = 6). In C, *P < 0.001 versus SKOV-3.
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SKOV-3 cell was 3.2 fold greater than the AUC for
OVCAR-3 cells (p < 0.0001). The data obtained are
consistent with SKOV-3 cells being significantly more
invasive than OVCAR-3 cells.
Characterisation of ovarian cancer cell
line-derived exosomes
Exosomes derived from OVCAR-3 and SKOV-3 were iso-
lated from cell-conditioned cultured media by differential
and buoyant density centrifugation. The presence of exo-
somal markers, CD63 and CD9 in exosomes isolated from
both cell lines was confirmed by Western blot (Figure 2A).
The exosomal particulate fraction isolated from OVCAR-3
and SKOV-3 were examined under transmission elec-
tron microscopy. Exosomes were identified as small vesi-
cles between 40–100 nm in a cup-shaped form from both
cell lines (Figure 2B). Finally, we compared the size
distribution of exosome preparations from OVAR-3 and
SKOV-3 cells supernatants using a nanoparticle trackingFigure 2 Characterisation of exosomes from ovarian cancer cell lines.
and CD9. S1-S4 and S5-S6 represent different exosomes isolation from OVC
micrograph of exosomes isolated from OVCAR-3 and SKOV-3 cells. (C) Nan
OVAR-3 (black) and SKOV-3 (red) exosomes (see Methods). In B, Scale bar 1analysis (NanoSight). OVAR-3 and SKOV-3 exosomes
were characterised by a particle size range of 50–130 nm
(Figure 2C).
Exosome release from OVCAR-3 and SKOV-3 cells
Exosomal protein release was expressed as total exoso-
mal protein (i.e. particulate material with a buoyant
density of 1.15 to 1.19 g/ml). OVCAR-3 cells released
0.44 ± 0.05 μg of exosomal protein per million cells per
24 h (n = 6; i.e. 6 different isolations from ~300 × 106
cells each) whereas SKOV-3 cells released 1.22 ± 0.11 μg
of exosomal protein per million cells per 24 h (n = 6;
i.e. 6 different isolations from ~300 × 106 cells each)
(Figure 3A). SKOV-3 cells released significantly more
exosomes (~2.7-folds) in 24 h compared to OVCAR-3
cells (p < 0.001). These results were confirmed using
ELISA (see Methods). The number of exosome particles
(NEP) released from SKOV-3 cells was ~2.2 fold higher
than the release from OVACR-3 cells (8.07 × 108 ± 5.9 ×
107 vs 1.63 × 109 ± 3.04 ×108 NEP in OVCAR-3 and(A) Representative image of western blot for the presence of CD63
AR-3 and SKOV-3 cells, respectively. (B) Representative electron
osight measurement of particle-size distribution in preparation from
00 nm.
Figure 3 Exosome releases from ovarian cancer cell lines. Exosomes were quantified in culture media of ovarian cancer cell lines using an
ELISA kit (see Methods). (A) Levels of exosome as presented as protein concentration from1x106 OVCAR-3 (white bar) and SKOV-3 cells (black
bar). (B) Quantification of number of exosome particles from OVCAR-3 (white circles) and SKOV-3 cells (black circles) per 106 cells. (C) Relationship
between number of exosome particles and exosomal protein concentration from OVCAR-3 and SKOV-3 cells. Fitted linear regression line with
95% confidence intervals (dotted lines). In A, ***P < 0.01 versus SKOV-3. In B, *P < 0.05 versus SKOV-3.
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NEP and exosomal protein pellet concentration were
significant correlated (Spearman’s r = 0.58; p = 0.037).
miRNA profile
The presence and abundance of specific microRNA (let-7
and miR-200 family) in both OVCAR-3 and SKOV-3
cell-derived and exosome-derived were determined. The
expression profile of miRNA (miR-let7 and miR-200) in
the two cell lines was significantly different (ANOVA,
p < 0.001). Post-hoc pairwise comparisons identified sig-
nificant differences in the expression of miR-200 but not
let-7 transcripts. (Bonferroni’s Multiple comparison test,
p < 0.01, Figure 4A).
In exosomes, miRNA expression profile (miR-let7 and
miR-200) was significantly different between OVCAR-
3- and SKOV-3-derived exosomes. exo-SKOV-3 expressed
significantly more (n = 6, p < 0.001) let-7 transcripts
compared to exo-OVCAR-3. Moreover, miR-200b and
miR-200c were only expressed in exo-OVCAR-3 reflecting
the miRNA signature in cells (Figure 4B). In addition, the
expression of miRNA transcript was significantly higher in
exosomes compared with the expression in cells (Figure 5A
and 5B).Discussion
The aim of this study was to test the hypothesis that
ovarian cancer cell invasiveness is associated with altered
release of exosomes and discordant exosomal sequestra-
tion of miRNA. Two ovarian cancer cell lines of epithe-
lial cell origin but with different invasive potentials were
used to test this hypothesis. In this study, the release of
exosomes from cells incubated under similar conditions,
was ~2-folds greater from SKOV-3 cells (high invasive)
than from OVCAR-3 cells (low invasive). Exosomes re-
leased by SKOV-3 cells contained a greater abundance
of let-7 miRNA transcripts than OVCAR-3 cells. When
exosomal miRNA content was compared with that of
the cell of origin, SKOV-3 cell-derived exosomes dis-
played no correlation with the cell origin. In contrast,
the miRNA profiles of OVCAR-3 cell-derived exosomes
and their cells of origin were highly correlated. The data
obtained established that the release and miRNA content
of exosomes differs significantly between ovarian cancer
cell lines and correlates with their invasive potential. Fur-
thermore, the data are consistent with the hypothesis that
selective packaging of specific miRNA transcripts into exo-
somes may represent a regulatory mechanism to maintain




















































































































Figure 4 Expression of let-7 and miR-200 families. Total microRNA was extracted using the Ambion mirVana PARIS Kit (Invitrogen). Real-time
PCR was performed with miScript SYBR Green Kit to compare let-7 and miR-200 family expression between ovarian cancer cell lines (OVAR-3 and
SKOV-3 cells) (A) and between cell-derived exosomes (exo-OVAR-3 and exo-SKOV-3) (B). Data are represented as mean ± SEM (n = 6). In A and B,
ANOVA p < 0.0001 between groups. In B, *p < 0.001 vs exo-SKOV-3.
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pressor activity.
In this study, we initially confirmed that SKOV-3 have a
greater capacity to invade than OVCAR-3 cells. Using a
3D in vitro culture model, we observed that SKOV-3 cells
were 2–3 times more invasive than OVCAR-3 cells (p <
0.0001). These data are consistent with previous publica-
tions [17].
Exosomes released from ovarian cancer cells in vitro
were isolated and characterised using well-established
methods [9,18,19,21-23]. Exosomes isolated from both
cell lines displayed characteristic morphology, buoyant
density (1.15 to 1.19 g/ml) and exosomal markers (i.e.CD63 and CD9 - members of the tetraspanin family and
one of the most abundant protein families present in
exosomes [24]. Previously, we [19] and others [7,21,25]
have successfully used such preparation of exosomes for
both proteomic analysis and RNA profiling.
In this study, we defined the release of exosomes from
ovarian cancer cells as the accumulation (in exosome-free
incubation medium) of CD63 and CD9 positive, particu-
late protein with a density of 1.15 to 1.19 g/ml. Exosome
release was cell type specific and correlated with cell inva-
siveness. When cells were incubated under identical con-
ditions, the release of exosomes from SKOV-3 cells was
more than 2-folds greater than that of OVCAR-3 cells
Figure 5 Comparison of miRNA transcripts expression between cells and exosomes. The miRNA expressions between cells and exosomes
in OVCAR-3 (A) and SKOV-3 (B). Data is represented by mean ± SEM (n = 6 per group).
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both OVCAR-3 [7,26] and SKOV-3 cells [9], however,
this is the first study to directly compare exosome
release from these cell lines.
In vivo, exosomes released from ovarian tumours may
be present in blood and other biological fluids. Previ-
ously, Taylor and Gercel-Taylor [9] isolated exosomes
from serum samples of women with ovarian cancer. The
concentration of exosomes was significantly elevated with
disease progression. The release of exosomes has also been
found to correlate with the invasiveness of other tumour
cell lines [27]. Even though the molecular mechanism
triggering the release of exosomes is poorly understood,
factors promoting exosome release have been identified,
including: hypoxia, anticancer drugs, thermal and oxida-
tive stress [28-31]. It is well established that heterogeneity
exists among tumour cells even in a single tumour [16].
This study further characterised ovarian cancer cell
exosome content by RT-PCR (miRNA content). Of par-
ticular note was the variation in expressions of two miRNA
families the let-7 and miR-200 transcripts. Iori, Visoneet al. [16] performed a large scale miRNA profiling of ovar-
ian cancer tissues. Let-7 was found to be down-regulated
and miR-200 transcripts were among the most significantly
up-regulated in epithelial ovarian cancer tissues compared
to normal tissues [16]. Both let-7 and miR-200 families
are tumour suppressors; let-7 repressing cell prolifera-
tion while miR-200 regulate epithelial to mesenchymal
transition [32]. Taylor and Gercel-Taylor [9] has com-
pared the expression of selected miRNA in exosomes
and originating cells. Expression levels of most miRNA
including let-7a, b, c, d, f and miR-200a, b, c have been
found to be the same, whereas let-7e was elevated in
exosomes compared to the cell, suggesting active selection
during miRNA compartmentalisation into exosomes [28].
The overall expressions of let-7 transcripts were more
abundant in OVCAR-3 cells than SKOV-3 cells. Interest-
ingly, in exosomes, let-7 transcripts were more abundant
in SKOV-3 cell derived exosomes. The low expression of
let-7 in SKOV-3 cells may be due to the compartmental-
isation into exosomes. Exosomes can either fuse with the
lysosomes to degrade their contents or release them out
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http://www.translational-medicine.com/content/12/1/4of the cells to decrease the expression of tumour suppres-
sor miRNAs, ultimately leading to their aggressive phe-
notype. The miR-200 transcripts were only present in
exosomes from OVCAR-3 as SKOV-3 did not express
miR-200 s in their cells. Previous studies have compared
miRNA expression in normal and cancerous tissue or cell
lines but have not compared expressions of different
metastatic potentials.
Recently, we demonstrated that proteins are selectively
packaged into placental cells exosomes by a process that,
at least in part, is regulated by the extracellular milieu
(i.e. low oxygen tension) [18,33]. In addition, Li et al.,
(2013) [34] reported that microvesicles (i.e. exosomes)
from glioma cells contain selective packaged miRNA that
modify the gene expression in cell target [34]. These ob-
servations are consistent with data obtained in this study
and the hypothesis that exosomal oligonucleotides are
selective packaged into exosome by endosomal process
(that are yet to be identified).
In this study, the expression of let-7 miRNA transcripts
was similar in both parent cell lines, however, miR-200
transcripts were only identified in OVCAR-3 cells. In con-
trast, exosomal expression of both let-7 and 200 miRNAFigure 6 Proposed model of ovarian cancer cell-derived exosome act
epithelial ovarian tumour, releasing exosomes. High invasive tumour cells (
involved in processes such as: cell death and survival, cellular movement, can
The let-7 family that are known to suppress cell proliferation was signifi
(from SKOV-3). On the other hand, the miR-200 family that suppress epi
derived from low invasive cells (from OVCAR-3) (2). The miRNA profile d
capacity (OVAR-3 versus SKOV-3) (3).transcripts displayed a dramatic cell specific variation. The
expression of let-7 miRNA transcripts in exosomes re-
leased from SKOV-3 cells was 7–20 times greater than in
exosomes released from OVCAR-3 cells. Similar, to the
expression profile in the parent cells, miR-200 transcripts
were only identified in exosomes from OVCAR-3. These
data are suggestive that ovarian cancer cell invasiveness is
not affected by the expression of let-7 miRNA transcripts
but that repression of miR-200 transcripts is associated
with increased invasive capacity. Furthermore, the data
obtained establish the selective and cell specific packaging
of miRNA transcripts into exosomes.
The expression of miRNA-200 transcripts in OVCAR-3
cells and their absence in the more aggressive SKOV-3 cell
line is consistent with the proposed involvement of miR-
200 s in tumor suppression via the inhibition of epithelial-
mesenchymal transition (EMT), the initiating step of
metastasis [32]. The expression of miR-200 s in OVCAR-3
may be a contributing factor in determining their lower
invasive potential when compared to SKOV-3 cells. In
support of this suggestion, the let-7 miRNA transcripts a-f
were identified in both cell types but were more abundant
in OVCAR-3.ion. Tumour cells with different invasion capacity exist in a single
SKOV-3) release significantly more exosomes (1), containing proteins
cer, cell-to-cell signalling and interaction, cellular growth and proliferation.
cantly more expressed in exosomes from high invasive exosomes
thelial to mesenchymal transition was only expressed in exosomes
iffers between exosomes derived from cells with different invasive
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Based on the data obtained in this study and on previ-
ously published observations, we propose the following
model of ovarian cancer cell exosome release and action
(Figure 6). Tumour cells with different invasion capacity
exist in a single epithelial ovarian tumour, releasing exo-
somes. High invasive tumour cells (SKOV-3) release sig-
nificantly more exosomes [1], containing proteins involved
in processes such as: cell death and survival, cellular move-
ment, cancer, cell-to-cell signalling and interaction, cellular
growth and proliferation. The let-7 family that is known to
suppress cell proliferation was significantly more expressed
in exosomes from high invasive exosomes (from SKOV-3).
On the other hand, the miR-200 family that suppresses
epithelial to mesenchymal transition was only expressed in
exosomes derived from low invasive cells (from OVCAR-
3) [2]. The miRNA profile differs between exosomes de-
rived from cells with different invasive capacity (OVCAR-3
versus SKOV-3) (3). Interestingly, significantly less let-7
family miRNA was expressed in the high invasive cells
(SKOV-3) although it was highly expressed in exosomes.
Within the tumour, high invasive tumour cell derived-
exosomes signal low invasive tumour cells and low inva-
sive tumour cell derived-exosomes can signal high invasive
tumour cells to increase invasion of recipient cells.
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